Federated Hermes’s Cartesian Therapeutics RNAC Stock Holding History

Federated Hermes’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,075	Closed	-$298K	–	2257
2022 Q1	$298K	Sell	8,075 -5,810	-42%	-$363K	﹤0.01%	1543
2021 Q4	$1.36M	Sell	13,885 -39	-0.3%	-$4.2K	﹤0.01%	1164
2021 Q3	$1.74M	Buy	13,924 +700	+5%	+$84.5K	﹤0.01%	1087
2021 Q2	$1.66M	Buy	13,224 +3,818	+41%	+$455K	﹤0.01%	1155
2021 Q1	$1.28M	Buy	+9,406	New	+$1.17M	﹤0.01%	1284

Other funds holding RNAC

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

NanoDimension Woodside, California $24.7M AUM 74.01% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Federated Hermes's RNAC Position: Q2 2022 in Review

Federated Hermes sold out of Cartesian Therapeutics (RNAC) in Q2 2022, closing a stake of 8,075 shares — an estimated $298K sold.

Federated Hermes first reported a position in RNAC in Q1 2021 and held it in 5 quarters. The position peaked at $1.74M in Q3 2021. 92 funds tracked by Wall St. Rank hold RNAC as of Q2 2022.

Federated Hermes reported no remaining Cartesian Therapeutics position as of Q2 2022 after selling out during the quarter.
Federated Hermes sold 8,075 Cartesian Therapeutics shares in Q2 2022, an estimated $298K.
Federated Hermes first reported a position in Cartesian Therapeutics in Q1 2021 and held it in 5 quarters.
Federated Hermes's Cartesian Therapeutics position peaked at $1.74M in Q3 2021.
92 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.